Dr Ioanna Parisi
Email:
Location:
- University College Hospital
GMC/GDC number:
7438463
Professional background
Dr Ioanna Parisi is a consultant gastroenterologist with a special interest in Inflammatory Bowel Disease (IBD) and with a broad experience in diagnosis and management of these diseases.
She is particularly interested in IBD in adolescence and a valuable member of the Adolescent IBD Service at UCLH with a dedicated weekly endoscopy list for adolescents only. She leads the capsule endoscopy service at UCLH which is amongst the higher volume capsule endoscopy services in the UK, performing small bowel, colon and pan-enteric capsule endoscopies at home and remotely.
Specialties
Research interests
IBD, adolescence, IBD transition, capsule endoscopy, liver disease
Languages spoken
Greek
Publications
1. Parisi, Ioanna et al. “Inflammation-based scores and hepatocellular carcinoma.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society vol. 20,12 (2014): 1529-30. doi:10.1002/lt.24017
2. Rossi RE, Parisi I, Despott EJ, et al. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. World J Gastroenterol. 2014;20(46):17352-17359. doi:10.3748/wjg.v20.i46.17352
3. Miller, C., Kwok, H., Harrow, P., Vega, R., Seward, E., Mehta, S., Rahman, F., McCartney, S., Parisi, I., Lim, S. H., Sharma, E., Samaan, M. A., Bancil, A., Kok, K. B., Shalabi, A., Johnston, E. L., Katarey, D., Taherzadeh, N., Murray, C., Sharip, M. T., … Bloom, S. (2022). Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab. Frontline gastroenterology, 13(5), 392–401. https://doi.org/10.1136/flgastro-2021-101906
4. Parisi, I., O'Beirne, J., Rossi, R. E., Tsochatzis, E., Manousou, P., Theocharidou, E., Hamilton, M., Murray, C., Epstein, O., & Burroughs, A. K. (2016). Elevated liver enzymes in inflammatory bowel disease: the role and safety of infliximab. European journal of gastroenterology & hepatology, 28(7), 786–791. https://doi.org/10.1097/MEG.0000000000000624
5. Selinger, C. P., Parkes, G. C., Bassi, A., Limdi, J. K., Ludlow, H., Patel, P., Smith, M., Saluke, S., Ndlovu, Z., George, B., Saunders, J., Adamson, M., Fraser, A., Robinson, J., Donovan, F., Parisi, I., Tidbury, J., Gray, L., Pollok, R., Scott, G., … Raine, T. (2019). Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients. Alimentary pharmacology & therapeutics, 50(9), 1009–1018. https://doi.org/10.1111/apt.15497
6. Samaan MA, de Jong D, Sahami S, Morgan S, Fragkos K, Subramaniam S, Kok K, Makanyanga J, Barnova I, Saravanapavan H, Parisi I, Di Caro S, Vega R, Rahman F, McCartney S, Bloom SL, van den Brink GR, Löwenberg M, Ponsioen CY, Buskens CJ, Tanis PJ, de Buck van Overstraeten A, DʼHoore A, Bemelman WA, DʼHaens GR. Incidence and Severity of Prepouch Ileitis: A Distinct Disease Entity or a Manifestation of Refractory Pouchitis? Inflamm Bowel Dis. 2016 Mar;22(3):662-8. doi: 10.1097/MIB.0000000000000593. PMID: 26383915.
7. Parisi I, Tsochatzis E, Wijewantha H, Rodríguez-Perálvarez M, De Luca L, Manousou P, Fatourou E, Pieri G, Papastergiou V, Davies N, Yu D, Luong T, Dhillon AP, Thorburn D, Patch D, O'Beirne J, Meyer T, Burroughs AK. Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria. Liver Transpl. 2014 Nov;20(11):1327-35. doi: 10.1002/lt.23969. PMID: 25088400.
8. Lazaraki G, Tzilves D, Parisi I, Tarpagos A. Magnetic resonance enteroclysis for Peutz-Jeghers syndrome. Ann Gastroenterol. 2011;24(3):219-220. PMID: 24713775; PMCID: PMC3959306.
9. Lazaraki G, Akriviadis E, Pilpilidis I, Parisi I, Tzilves D, Tarpangos A. Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia. Am J Gastroenterol. 2011 Dec;106(12):2204-6. doi: 10.1038/ajg.2011.287. PMID: 22138950.